182 related articles for article (PubMed ID: 34233962)
21. Overexpression of c-myc is associated with adverse clinical features and worse overall survival in multiple myeloma.
Szabo AG; Gang AO; Pedersen MØ; Poulsen TS; Klausen TW; Nørgaard P
Leuk Lymphoma; 2016 Nov; 57(11):2526-34. PubMed ID: 27243588
[TBL] [Abstract][Full Text] [Related]
22. A Next-Generation Sequencing Strategy for Evaluating the Most Common Genetic Abnormalities in Multiple Myeloma.
Jiménez C; Jara-Acevedo M; Corchete LA; Castillo D; Ordóñez GR; Sarasquete ME; Puig N; Martínez-López J; Prieto-Conde MI; García-Álvarez M; Chillón MC; Balanzategui A; Alcoceba M; Oriol A; Rosiñol L; Palomera L; Teruel AI; Lahuerta JJ; Bladé J; Mateos MV; Orfão A; San Miguel JF; González M; Gutiérrez NC; García-Sanz R
J Mol Diagn; 2017 Jan; 19(1):99-106. PubMed ID: 27863261
[TBL] [Abstract][Full Text] [Related]
23. [Molecular genetic methods for the prognostic criteria in multiple myeloma].
Mikala G; Jákó J; Vályi-Nagy I
Orv Hetil; 2005 Aug; 146(32):1673-82. PubMed ID: 16149245
[TBL] [Abstract][Full Text] [Related]
24. The combination of C-Myc rearrangement and 1q21 gain is associated with poor prognosis in multiple myeloma.
Jin Y; Yu X; Du J; Li H; Tang W; Jia C; Zan Y; Chen M; Zhang Y; Yu M; Rong W; Zhou D; Zhuang J
Ann Hematol; 2021 May; 100(5):1251-1260. PubMed ID: 33686491
[TBL] [Abstract][Full Text] [Related]
25. Linked-read whole-genome sequencing resolves common and private structural variants in multiple myeloma.
Peña-Pérez L; Frengen N; Hauenstein J; Gran C; Gustafsson C; Eisfeldt J; Kierczak M; Taborsak-Lines F; Olsen RA; Wallblom A; Krstic A; Ewels P; Lindstrand A; Månsson R
Blood Adv; 2022 Sep; 6(17):5009-5023. PubMed ID: 35675515
[TBL] [Abstract][Full Text] [Related]
26. [Prognostic significance of sequencing-based MRD detection in multiple myeloma].
Takamatsu H
Rinsho Ketsueki; 2015 Aug; 56(8):989-96. PubMed ID: 26345557
[TBL] [Abstract][Full Text] [Related]
27. Heterogeneous pattern of chromosomal breakpoints involving the MYC locus in multiple myeloma.
Fabris S; Storlazzi CT; Baldini L; Nobili L; Lombardi L; Maiolo AT; Rocchi M; Neri A
Genes Chromosomes Cancer; 2003 Jul; 37(3):261-9. PubMed ID: 12759924
[TBL] [Abstract][Full Text] [Related]
28. Upgraded Standardized Minimal Residual Disease Detection by Next-Generation Sequencing in Multiple Myeloma.
Yao Q; Bai Y; Orfao A; Kumar S; Chim CS
J Mol Diagn; 2020 May; 22(5):679-684. PubMed ID: 32151713
[TBL] [Abstract][Full Text] [Related]
29. Analytical evaluation of the clonoSEQ Assay for establishing measurable (minimal) residual disease in acute lymphoblastic leukemia, chronic lymphocytic leukemia, and multiple myeloma.
Ching T; Duncan ME; Newman-Eerkes T; McWhorter MME; Tracy JM; Steen MS; Brown RP; Venkatasubbarao S; Akers NK; Vignali M; Moorhead ME; Watson D; Emerson RO; Mann TP; Cimler BM; Swatkowski PL; Kirsch IR; Sang C; Robins HS; Howie B; Sherwood A
BMC Cancer; 2020 Jun; 20(1):612. PubMed ID: 32605647
[TBL] [Abstract][Full Text] [Related]
30. Dysregulation of c-myc in multiple myeloma.
Kuehl WM; Brents LA; Chesi M; Huppi K; Bergsagel PL
Curr Top Microbiol Immunol; 1997; 224():277-82. PubMed ID: 9308252
[TBL] [Abstract][Full Text] [Related]
31. MYC amplifications in myeloma cell lines: correlation with MYC-inhibitor efficacy.
Holien T; Misund K; Olsen OE; Baranowska KA; Buene G; Børset M; Waage A; Sundan A
Oncotarget; 2015 Sep; 6(26):22698-705. PubMed ID: 26087190
[TBL] [Abstract][Full Text] [Related]
32. MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA/LYSA study.
Copie-Bergman C; Cuillière-Dartigues P; Baia M; Briere J; Delarue R; Canioni D; Salles G; Parrens M; Belhadj K; Fabiani B; Recher C; Petrella T; Ketterer N; Peyrade F; Haioun C; Nagel I; Siebert R; Jardin F; Leroy K; Jais JP; Tilly H; Molina TJ; Gaulard P
Blood; 2015 Nov; 126(22):2466-74. PubMed ID: 26373676
[TBL] [Abstract][Full Text] [Related]
33. Prognostic value of sequencing-based minimal residual disease detection in patients with multiple myeloma who underwent autologous stem-cell transplantation.
Takamatsu H; Takezako N; Zheng J; Moorhead M; Carlton VEH; Kong KA; Murata R; Ito S; Miyamoto T; Yokoyama K; Matsue K; Sato T; Kurokawa T; Yagi H; Terasaki Y; Ohata K; Matsumoto M; Yoshida T; Faham M; Nakao S
Ann Oncol; 2017 Oct; 28(10):2503-2510. PubMed ID: 28945825
[TBL] [Abstract][Full Text] [Related]
34. Characterization of MYC translocations in multiple myeloma cell lines.
Dib A; Gabrea A; Glebov OK; Bergsagel PL; Kuehl WM
J Natl Cancer Inst Monogr; 2008; (39):25-31. PubMed ID: 18647998
[TBL] [Abstract][Full Text] [Related]
35. Genomic Aberrations in Multiple Myeloma.
Manier S; Salem K; Glavey SV; Roccaro AM; Ghobrial IM
Cancer Treat Res; 2016; 169():23-34. PubMed ID: 27696256
[TBL] [Abstract][Full Text] [Related]
36. Impact of C-Myc gene-related aberrations in newly diagnosed myeloma with bortezomib/dexamethasone therapy.
Sekiguchi N; Ootsubo K; Wagatsuma M; Midorikawa K; Nagata A; Noto S; Yamada K; Takezako N
Int J Hematol; 2014 Mar; 99(3):288-95. PubMed ID: 24496825
[TBL] [Abstract][Full Text] [Related]
37. Bone morphogenetic proteins induce apoptosis in multiple myeloma cells by Smad-dependent repression of MYC.
Holien T; Våtsveen TK; Hella H; Rampa C; Brede G; Grøseth LA; Rekvig M; Børset M; Standal T; Waage A; Sundan A
Leukemia; 2012 May; 26(5):1073-80. PubMed ID: 21941367
[TBL] [Abstract][Full Text] [Related]
38. Integrative network analysis identifies novel drivers of pathogenesis and progression in newly diagnosed multiple myeloma.
Laganà A; Perumal D; Melnekoff D; Readhead B; Kidd BA; Leshchenko V; Kuo PY; Keats J; DeRome M; Yesil J; Auclair D; Lonial S; Chari A; Cho HJ; Barlogie B; Jagannath S; Dudley JT; Parekh S
Leukemia; 2018 Jan; 32(1):120-130. PubMed ID: 28642592
[TBL] [Abstract][Full Text] [Related]
39. Clinical implications of chromosomal abnormalities in multiple myeloma.
Terpos E; Eleutherakis-Papaiakovou V; Dimopoulos MA
Leuk Lymphoma; 2006 May; 47(5):803-14. PubMed ID: 16753864
[TBL] [Abstract][Full Text] [Related]
40. Development of an RNA sequencing-based prognostic gene signature in multiple myeloma.
Zamani-Ahmadmahmudi M; Nassiri SM; Soltaninezhad F
Br J Haematol; 2021 Jan; 192(2):310-321. PubMed ID: 32410217
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
